AXSOME THERAPEUTICS INC (AXSM)
US05464T1043 - Common Stock
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
Here are our top three choices for biotech stocks with blockbuster drug pipelines that could pay off massively in the future.
Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors
/PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the nomination of...
AXSM Crosses Above Key Moving Average Level
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
Stocks that work for billionaires aren't necessarily appropriate for every investor.
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis ...
2 Under-the-Radar Growth Stocks to Consider
Don't ignore these innovative companies.
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to...
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically significant...
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The price could be right for these three biopharma stocks.
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Axsome Therapeutics Enters Oversold Territory (AXSM)
AXSM Crosses Below Key Moving Average Level
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential.
3 Biotech Stocks to Buy and Hold for the Next 10 Years
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.